A5029952866- Glioma Diagnosis and Treatment
- Brain Metastases and Treatment
- Meningioma and schwannoma management
- Chromatin Remodeling and Cancer
- Fibroblast Growth Factor Research
- Cancer, Hypoxia, and Metabolism
- Neuroblastoma Research and Treatments
- Sarcoma Diagnosis and Treatment
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- CNS Lymphoma Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Retinoids in leukemia and cellular processes
- Neurofibromatosis and Schwannoma Cases
- Management of metastatic bone disease
- Histone Deacetylase Inhibitors Research
- Pancreatic and Hepatic Oncology Research
- Lymphoma Diagnosis and Treatment
- Radiopharmaceutical Chemistry and Applications
- Radiomics and Machine Learning in Medical Imaging
- Gastric Cancer Management and Outcomes
- Cancer Research and Treatments
- Cancer Mechanisms and Therapy
- Immune cells in cancer
- ATP Synthase and ATPases Research
Takeda (United States)
2023-2025
Northwestern University
2014-2024
Astellas Pharma (United States)
2021-2023
Midwestern University
2007-2022
Northwestern Medicine
2012-2022
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
2006-2022
University Medical Center
2020
Abbott (United States)
2005-2018
Agenus (United States)
2016-2018
Memorial Sloan Kettering Cancer Center
2002-2017
NovoTTF-100A is a portable device delivering low-intensity, intermediate frequency electric fields via non-invasive, transducer arrays. Tumour Treatment Fields (TTF), completely new therapeutic modality in cancer treatment, physically interfere with cell division.Phase III trial of chemotherapy-free treatment NovoTTF (20-24h/day) versus active chemotherapy the patients recurrent glioblastoma. Primary end-point was improvement overall survival.Patients (median age 54 years (range 23-80),...
Cilengitide, an inhibitor of alphavbeta3 and alphavbeta5 integrin receptors, demonstrated minimal toxicity durable activity across a wide range doses administered to adults with recurrent glioblastoma multiforme (GBM) in prior phase I study. The current multicenter II study was conducted evaluate the safety cilengitide GBM patients at first recurrence.Eligible were randomly assigned receive either 500 or 2,000 mg twice weekly on continuous basis. Patients assessed every 4 weeks. primary end...
A multicenter phase II study was conducted to assess the efficacy of rituximab, methotrexate, procarbazine, and vincristine (R-MPV) followed by consolidation reduced-dose whole-brain radiotherapy (rdWBRT) cytarabine in primary CNS lymphoma.Patients received induction chemotherapy with R-MPV (five seven cycles); those achieving a complete response (CR) rdWBRT (23.4 Gy), otherwise, standard WBRT offered (45 Gy). Consolidation given after radiotherapy. The end point 2-year progression-free...
Phase I: To determine the maximum tolerated doses, toxicities, and pharmacokinetics of imatinib mesylate (Gleevec) in patients with malignant gliomas taking enzyme-inducing antiepileptic drugs (EIAED) or not EIAED. II: therapeutic efficacy imatinib.Phase I component used an interpatient dose escalation scheme. End points phase II were 6-month progression-free survival response.Fifty enrolled (27 EIAED 23 non-EIAED). The for non-EIAED was 800 mg/d. Dose-limiting toxicities neutropenia, rash,...
Our goals were to evaluate the safety of adding rituximab methotrexate (MTX)-based chemotherapy for primary CNS lymphoma, determine whether additional cycles induction improve complete response (CR) rate, and examine effectiveness toxicity reduced-dose whole-brain radiotherapy (WBRT) after CR.Thirty patients (17 women; median age, 57 years; Karnofsky performance score, 70) treated with five seven (rituximab, MTX, procarbazine, vincristine [R-MPV]) as follows: day 1, 500 mg/m2; 2, MTX 3.5...
PURPOSE To assess whether reirradiation (re-RT) and concurrent bevacizumab (BEV) improve overall survival (OS) and/or progression-free (PFS), compared with BEV alone in recurrent glioblastoma (GBM). The primary objective was OS, secondary objectives included PFS, response rate, treatment adverse events (AEs) including delayed CNS toxicities. METHODS NRG Oncology/RTOG1205 is a prospective, phase II, randomized trial of re-RT versus alone. Stratification factors age, resection, Karnofsky...
Abstract Metastases to the spine represent a challenging problem in an oncology practice. Treatment decisions require multidisciplinary review. Radiation therapy remains primary treatment for metastatic spinal tumor, but advances radiation therapy, chemotherapy, and surgery have changed roles of each lead improved patient outcomes. Regardless treatment, diagnosis before development significant neurologic functional deficits improve Physician awareness appropriate imaging greatly assist early...
Brain metastases (BM) are among the most devastating and debilitating complications of melanoma. This retrospective study was conducted to gain a better understanding patient disease characteristics that have greatest impact on overall survival in melanoma patients with BM; therapeutic interventions were also assessed. The records all diagnosed cutaneous BM who seen at Memorial Sloan-Kettering Cancer Center between 1991 2001 retrospectively reviewed. A variety factors, including age...
Retrospective review of prospectively maintained institutional spine database.To assess the pain, neurologic, and functional outcome patients with metastatic spinal cord compression using a posterolateral transpedicular approach circumferential fusion.Patients metastases often have patterns disease requiring both an anterior posterior surgical decompression fusion. For whose concurrent illness or previous surgery makes difficult, was used to resect involved vertebral bodies, elements,...
This phase II study evaluated the efficacy and safety of AMG 102 (rilotumumab), a fully human monoclonal antibody against hepatocyte growth factor/scatter factor (HGF/SF), in patients with recurrent glioblastoma (GBM). Patients histologically confirmed, measurable GBM or gliosarcoma (World Health Organization grade 4) ≤3 relapses prior systemic therapies received (10 20 mg/kg) by infusion every 2 weeks. The primary endpoint was best confirmed objective response rate (central assessment) per...
Abstract BACKGROUND: The authors evaluated a 3‐week schedule of bevacizumab in patients with recurrent high‐grade glioma (HGG). METHODS: Patients received 15 mg/kg every 3 weeks and were 6 until tumor progression. Tissue correlates used to quantify content vascular endothelial growth factor A (VEGFA) receptor‐2 (VEGFR2). RESULTS: Of 61 who treated (35 men 26 women; median age, 52 years; age range, 21‐78 years), 50 had glioblastoma multiforme (GBM), 11 anaplastic (AG). number previous...
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Central Nervous System (CNS) Cancers provide interdisciplinary recommendations managing adult CNS cancers. Primary and metastatic brain tumors are a heterogeneous group of neoplasms with varied outcomes management strategies. These Insights summarize the Panel's discussion highlight notable changes 2015 update. This article outlines data provides insight into panel decisions regarding adjuvant radiation chemotherapy...
Increased mitogenic signaling and angiogenesis, frequently facilitated by somatic activation of EGF receptor (EGFR; ErbB1) and/or loss PTEN, VEGF overexpression, respectively, drive malignant glioma growth. We hypothesized that patients with recurrent glioblastoma would exhibit differential antitumor benefit based on tumor PTEN/EGFRvIII status when treated the antiangiogenic agent pazopanib ErbB inhibitor lapatinib.A phase II study evaluated activity 400 mg/d plus lapatinib 1,000 in grade 4...
Panobinostat is a histone deacetylase inhibitor with antineoplastic and antiangiogenic effects in glioma that may work synergistically bevacizumab. We conducted multicenter phase II trial of panobinostat combined bevacizumab patients recurrent high-grade (HGG). Patients HGG were treated oral 30 mg 3 times per week, every other combination 10 mg/kg week. The primary endpoint was 6-month progression-fee survival (PFS6) rate for participants glioblastoma (GBM). anaplastic (AG) evaluated as an...
In 2010, an estimated 22,020 new cases of primary brain and other nervous system neoplasms were diagnosed in the United States, 1 approximately 13,140 deaths occurred from these tumors.The incidence malignant tumors has been increasing over past 30 years, especially elderly persons. 2 Metastatic disease to central (CNS) occurs much more frequently, with 10 times that tumors.Between 20% 40% patients systemic cancer will develop metastases.